Oddity Tech Ltd.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Oran Holtzman
- Full Time Employees
- 658
- Sector
- Consumer Defensive
- Industry
- Household & Personal Products
- Address
- 8 Haharash Street Jaffa Israel 6761304
- IPO Date
- Jul 19, 2023
- CIK
- 0001907085
- Website
- oddity.com
- Similar Companies
- Business
- Oddity Tech Ltd. (Nasdaq: ODD) operates as a consumer technology company that develops and scales digital-first brands in the beauty, wellness and medical telehealth industries through an AI-driven online platform leveraging data science, machine learning and computer vision. The company offers core products including foundation, concealer, lipstick, mascara, eye, brow and lip makeup; skincare and haircare treatments; supplements; and makeup tools under the IL MAKIAGE and SpoiledChild brands; alongside an expanding portfolio of medical-grade dermatology products such as creams, supplements and cosmetics addressing acne, hyperpigmentation and eczema via its new METHODIQ telehealth platform; with ODDITY LABS biotechnology center deploying AI-based molecule discovery for novel ingredients. Founded in 2013 and headquartered in Tel Aviv, Israel, with additional offices in New York City and a biotechnology lab in Boston, Oddity Tech serves consumers worldwide, primarily in the United States and internationally. Recent developments include the November 2025 launch of the METHODIQ brand and telehealth platform in partnership with board-certified dermatologists for AI-powered personalized skincare; the January 2025 acquisition of Fionic's AI intellectual property and elite research team to enhance predictive modeling and consumer engagement algorithms; and raised full-year 2025 revenue guidance to $806-$809 million reflecting 24-25% growth amid record Q3 results.
ODDITY Tech Ltd (ODD) Shares Surge 3.4% -- What GF Score of 77 Tells Investors
Empowered Funds LLC Takes Position in ODDITY Tech Ltd. $ODD
Amundi Grows Position in ODDITY Tech Ltd. $ODD
Fosun International Wins Three Awards from Global Banking & Finance Review, Gaining International Recognition for its ESG Performance, Corporate Social Responsibility, and Brand Strength
U.S. FDA Grants Orphan Drug Designation to Zai Lab's DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
ODDITY to Announce Second Quarter 2026 Financial Results on September 9, 2026
Fosun International Garners Five Awards from Corporate Governance Asia
Options Now Trading on SPAX, Giving Traders Leveraged, Optionable Exposure to SpaceX
Oddity Tech: Recovery Proof Is Still Missing (Rating Downgrade)
Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
Why Oddity Tech Stock Is Plummeting Today
Oddity Tech Ltd. (ODD) Q1 2026 Earnings Call Transcript
Oddity Tech (ODD) Reports Q1 Loss, Tops Revenue Estimates
ODDITY Tech Reports First Quarter 2026 Results, Makes Progress Toward Normalization
Oddity Tech: Cheap, But The Ad Fix Still Has To Show Up
ODDITY to Announce First Quarter 2026 Financial Results on June 2, 2026
ODD 9-DAY DEADLINE ALERT: ODDITY Tech. (ODD) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action - Hagens Berman
ODD DEADLINE ALERT: Hagens Berman Alerts ODDITY Tech. (ODD) Investors to Today's Lead Plaintiff Deadline in Securities Class Action
ODDITY DEADLINE TODAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ODDITY Tech Ltd. Investors to Secure Counsel Before Important May 11 Deadline in Securities Class Action - ODD
Bronstein, Gewirtz & Grossman LLC Urges ODDITY Tech Ltd. Investors to Act: Class Action Filed Alleging Investor Harm